China will allow the use of data from overseas clinical trials for approvals of new drugs, in a move likely to enable multinationals to bring products to the world’s second-largest pharmaceutical market more quickly.
Pharmaceutical approvals in China can take up to seven years longer than in Europe and the US due to a requirement that overseas trials be at an advanced stage before Chinese trials can begin. The China drugs market generated $117bn in sales last year, according to the QuintilesIMS consultancy.
But companies will, in some cases, now be allowed to avoid Chinese trials altogether by using data gathered overseas, the ruling Communist party’s Central Committee said on Sunday.
您已閱讀25%（691字），剩余75%（2092字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。